Status: Not yet recruiting
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study
Participants needed: 18
Trial details
Phase: Phase 1Age: 30-80Biological sex: AllType: InterventionalSponsor: Voyager TherapeuticsUpdated: Aug 13, 2026
Eligibility criteria
Male or female participants aged 55 to 80 years (inclusive) at Screening or aged... [+5]
Seropositive for anti-AAV9 antibodies at Screening. [+10]